fda warning compounding semaglutide october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our New project announcement: HHS‑OIG is

Try our GLP-1 weight loss-friendly products that boost your weight loss journey and healthy lifestyle to a whole new level.

Recommend to reduce dosing frequency to every other day if experiencing side effects such nausea, constipation, diarrhea and/or gastric discomfort

For many people, the real challenge lies in how the body regulates hunger, metabolism, and energy balance

A two-component co-formulation of Cagrilintide and a GLP-1class peptide supplied for controlled research environments

Saxenda peeing a lot: discover why some patients experience increased urination with Saxenda, when to seek medical advice, and practical management strategies aligned with UK clinical guidance.

Patients with multiple comorbidities, especially those with limited treatment options, are significantly more likely to initiate GLP1 therapy